*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Summary Sentence: Suhasa Kodandaramaiah and James Kratzer presenting
Full Summary: The Graduate and Post-Doc (GaP) Seminar Series is a weekly event of research presentations by two graduate students or post-docs conducting bio-related research. The series is organized and sponsored by the Parker H. Petit Institute for Bioengineering and Bioscience (IBB) with additional support from the Wallace H. Coulter Department of Biomedical Engineering. It is held every Wednesday at 12:00pm in IBB 1128 and refreshments are provided. If your research group or department would like to present at future seminars, please contact Manu Platt, PhD.
GaP Seminar Series
Suhasa Kodandaramaiah
James KratzerSuhasa Kodandaramaiah - Advisor, Craig Forest, PhD
"Robotics from in vivo Patch Clamp Electrophysiology"
Wholecell patchclamp electrophysiology of neurons is a gold-standard technique for high-fidelity analysis of the biophysical mechanisms of neural computation and pathology, but requires great skill to perform. We have developed a robot systems that automatically performs patch clamping in vivo demonstrating good yield, throughput and quality of automated recordings in mouse cortex and hippocampus.
James Kratzer - Advisor, Eric Gaucher, PhD
"Reengineering a Human-like Uricase for the Treatment of Gout"
We are reengineering a “human-like” uricase to safely and efficiently alleviate gouty arthritis. This research addresses the unmet medical need in the enzymatic management of gout by developing a uricase better tolerated by patients. We have developed a lead that has comparable in vitro activity and enhanced in vivo stability compared to the Krystexxa, the only approved uricase gout treatment.
